Actively Recruiting
MDMA-Assisted Therapy for Mental Healthcare Providers
Led by Rachel Yehuda · Updated on 2026-03-27
30
Participants Needed
1
Research Sites
201 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a phase 1, open-label study to assess changes in mental well-being following MDMA administration within a therapeutic setting, in mental health providers who are in training to become MDMA assisted therapists. Secondary outcome measures will examine the effects on provider burnout, provider self-efficacy, mood, self-compassion, quality of life, and other psychological factors. Participants will work with a co-therapy pair as they engage in a preparatory session, one experimental session with MDMA, and an integration session the following day.
CONDITIONS
Official Title
MDMA-Assisted Therapy for Mental Healthcare Providers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least 18 years old at the time of signing informed consent
- Fluent in English
- Able to swallow pills
- Agree to have study visits audiovisually recorded
- Able to provide a contact person reachable if participant becomes unwell or unreachable
- Licensed, license-eligible, or trainee in a relevant healthcare or mental health profession
- Learning or certified to conduct MDMA-assisted therapy through the Lykos MDMA-Assisted Therapy Training program or authorized affiliate
- Body weight of at least 45 kilograms (100 pounds)
You will not qualify if you...
- Started a new form of psychiatric or mental health care within 12 weeks before enrollment
- Current alcohol or cannabis use disorder within the past 12 months
- Substance use disorder within the past 12 months
- Suicidal thoughts within the last 6 months
- Repetitive or recent use of Ecstasy/MDMA
- Currently enrolled in another clinical study involving investigational treatment without approval
- Current or recent (within 3 months) major depressive episode or current anxiety disorder
- Current eating disorder with compensatory behaviors
- History or current primary psychotic disorder or bipolar disorder
- Previous participation in a clinical trial involving MDMA administration
- Personal relationship with the site investigator
- Pregnant, nursing, or able to become pregnant without effective contraception
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Parsons Research Center for Psychedelic Healing
New York, New York, United States, 10025
Actively Recruiting
Research Team
L
Lily Fischer
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here